Percara Enterprises

Percara is a biotechnology company and a subsidiary of BridgeBio Pharma focused on developing novel therapies for rare skeletal dysplasias, specifically achondroplasia. The company's lead research program, PC-002, is a soluble recombinant human FGFR3 decoy receptor designed to sequester fibroblast growth factors and prevent the overactive signaling that inhibits bone growth. By targeting the underlying genetic mechanism of achondroplasia, Percara aims to restore normal chondrocyte proliferation and bone development in affected individuals. The company operates within the BridgeBio hub-and-spoke model, utilizing centralized expertise to advance its specialized pipeline. While the asset remains part of the BridgeBio portfolio, much of the clinical focus has shifted toward other FGFR3-targeting modalities within the parent organization.